Email Updates

You are here

Webinar & Meeting Reports

  • May 20, 2014

    On May 14, the US Centers for Disease Control (CDC) and the US Public Health Service released new clinical guidelines on using daily oral TDF/FTC (also known as Truvada) as PrEP for HIV prevention. This type of guideline is used by the US government to set national norms for health providers. It is the first such national guideline issued anywhere for PrEP use. Representatives from the CDC provided an overview of the guidelines and answer questions about their content and implications. This was followed by a moderated discussion.

  • May 19, 2014

    This webinar, which coincided with observances of HIV Vaccine Awareness Day (May 18th) provided an update on follow-on trials that build on the positive findings from the RV144 Thai trial; what looks hopeful in early clinical and pre-clinical science; and why the field has increasing optimism about finding effective HIV-specific antibodies, the "holy grail" of anti-HIV immune responses. As always, your comments and questions help guide the discussion.

  • May 6, 2014

    A webinar in memory of HIV prevention pioneer and revolutionary Jeff McConnell. A respected and passionate sociologist, Jeff (who passed away at the age of 49 this past February) was also a gay man living with HIV, and his identity was an important component of the science he conducted. His brilliant, human-touch research on gay men’s sex, sexuality, and various prevention methodologies involving treatment and PrEP was groundbreaking, visionary, and way ahead of most of us.

  • April 28, 2014

    The fourth webinar in AVAC's Research & Reality series, a year-long dialogue about prevention research and advocacy, this call provided a forum to learn about and discuss key issues around women and the HIV prevention agenda, including challenges around marketing of and adherence to new prevention options.

  • April 24, 2014

    Rectal douching is a relatively common behavior across the world. So, should we be thinking seriously about developing a rectal microbicide as a douche? What do we know about rectal douching behavior globally? What are some of the most popular products used and by whom? What are the implications for rectal microbicide research and development? What are the gaps in rectal douche science?

  • April 24, 2014

    A webinar discussing the ongoing Shaping the Health of Adolescents in Zimbabwe (SHAZ!) study. 2014 AVAC Fellow Definate Nhamo reviewed key findings from SHAZ! and previewed how she will use them to shape some of her advocacy in her 2014 Fellowship year.

  • April 22, 2014

    Hosted jointly by NAM and AVAC, the second webinar in the 2014 series covered harm reduction, pre-exposure prophylaxis (PrEP) and Hepatitis C prevention in people who use drugs, with news from relevant studies and new initiatives in Europe.

  • April 7, 2014

    This was the third webinar in AVAC's Research & Reality series, a year-long dialogue about prevention research and advocacy. The call provided a forum to learn about and discuss recent data and ongoing research on long-acting ARV injectables.

  • April 3, 2014

    The Los Angeles County PrEP Workgroup and AVAC’s PxROAR program presented the webinar The Doc is In: Prescribing, Managing and Billing for PrEP (pre-exposure prophylaxis) for HIV PreventionThis webinar aimed to address some of the key issues around PrEP prescribing, such as concerns around drug resistance, cost and reimbursement, risk assessment and side effects, among others.

  • March 10, 2014

    In this call we learned about and discussed proposed research to directly evaluate how different family planning methods might impact HIV risk.